In this episode, Hall welcomes Jane Zhang Ph.D., Founder & CEO of Remmie.

Remmie Health is a medical technology startup targeting the most common reason for a sick child visit – otitis media (ear infection), with 16 million episodes per year in the U.S. alone. Remmie’s first product is an at-home smart otoscope that enables telemedicine and tracking of ENT infections. This patent-pending device empowers parents to monitor ear, nose, and throat (ENT) symptoms, and it can be used safely in the home.

It all started when Jane’s son had an ear infection soon after starting child care. After a long year with four infections and an especially stubborn episode that lasted 40 days, Jane decided to do something about it…

Remmie is passionate about empowering parents to evaluate these symptoms at home and providing telemedicine doctors with a precise view of their patients’ symptoms to improve diagnostic accuracy.

Jane has 15 years of experience in healthcare product R&D and operations including in Becton, Dickinson, and Amgen. She is the Affiliate Assistant Professor with the University of Washington in biomedical diagnostic technologies. Jane has a Ph.D. in Biomedical Engineering from Boston University and an MBA from UCLA.

Jane shares with Hall the reason behind founding Remmie. She speaks about the growth rate of the medtech sector and some of the challenges it faces.

You can visit Remmie at www.remmiehealth.com, via LinkedIn at www.linkedin.com/company/remmiehealth/, and via Twitter at www.twitter.com/RemmieHealth.     

Jane can be contacted via email at jane@remmiehealth.com.  

For a full transcript, click here.

Copyright (c) 2024, Hall Martin and investorconnect.org. All rights reserved.

Disclaimer:
Hall T Martin is the director of Investor Connect, which is a 501(c)(3) nonprofit dedicated to the education of investors for early-stage funding. All opinions expressed by Hall and podcast guests are solely their own opinions and do not reflect the opinion of Investor Connect. This podcast is for informational purposes only and should not be relied upon for the basis of investment decisions.